Fourth European
Congress of Virology
Cernobbio, Italy
April 7 – 11, 2010
PRECLINICAL STUDIES ON MYRCLUDEX B, A NOVEL ENTRY INHIBITOR
FOR HEPATITS B (HBV) AND HEPATITIS DELTA VIRUS (HDV) INFECTIONS
S. Urban (1), A. Schulze (1), A. Schieck (2), C. Gähler (1), Y. Ni (1), A. Meier (1), A.
Alexandrov (3) and W. Mier (2)
(1) Department Of Infectious Diseases, Molecular Virology, University Clinics Heidelberg,
Heidelberg, Germany, (2) Department Of Nuclear Medicine, University Clinics Heidelberg,
Heidelberg, Germany and (3) Vision 7 GmbH, Frankfurt/Main, Germany 作者: 走遍四方 时间: 2011-3-4 15:51
From Viral hepatitis By Howard C. Thomas, Stanley M. Lemon, Arie J. Zuckerman[2005]
"If the production of new virions could be completely blocked, cccDNA should eventually be eliminated as a result of either death of infected hepatocytes or intracellular decay. The lifespan of infected hepatocytes appears to be variable depending on the severity of liver disease and intracellular turnover of cccDNA is probably similarly variable."
"如果新的病毒颗粒的生产量将完全被封锁,cccDNA的最终应该被淘汰,要么被感染的肝细胞或细胞内腐烂死亡。受感染的肝细胞寿命似乎是变量取决于疾病严重程度,肝细胞内cccDNA的
周转额变可能是同样的."
"REP 9AC is a DNA-based amphipathic polymer which has been shown to potently inhibit the release of HBsAg from infected hepatocytes."
REP9AC是一种DNA为基础的两亲性聚合物,已被证明potently抑制感染的肝细胞表面抗原的释放。 作者: StephenW 时间: 2011-3-7 12:48
From liver411: FLSH:http://easl2010.ihepa.com/28-323-726.html
Slide no. 3
Concept of entry inhibition:
1. Protection of non-infected hepatocytes during removal of infected hepatocytes may improve the immulogical control and clearance of HBV
2. Prevention of vertical transmission, transplant reinfection..
[Stephen]